Eli Lilly and Company

About: Eli Lilly and Company is a company organization based out in Indianapolis, Indiana, United States. It is known for research contribution in the topics: Population & Receptor. The organization has 17826 authors who have published 22835 publications receiving 946714 citations. The organization is also known as: Eli Lily.

Medication dispensing device

Abstract: A medication dispensing device comprising a cartridge for containing an injectable product therein and an injector attached to the cartridge. The injector includes a drive mechanism comprising a dosage sleeve having a dosage knob at the proximal end thereof and a threaded rod coupled to the sleeve and axially advanceable into the cartridge upon clockwise rotation of the knob for dialing up a desired dosage to be injected. A ratchet mechanism is disposed in the injector housing and includes a rotatable piece secured to the dosage sleeve for rotation therewith and a locking seat in engagement with the rotatable piece. The ratchet mechanism permits rotational movement of the sleeve in the clockwise direction only. A disengaging mechanism is secured to the housing of the LCD assembly and includes a pin that extends into and engages the rotatable piece of the ratchet mechanism such that axial movement of the pin causes corresponding axial movement of the stationary piece. Upon depressing the outer surface of the disengaging mechanism, the pin and the rotatable piece are moved axially away from the seat sufficiently enough to permit a user to rotate the dosage knob in a counterclockwise direction to accurately dial back an accidental overdose measurement without removing the cartridge from the injector.

Factors Influencing Acute Weight Change in Patients With Schizophrenia Treated With Olanzapine, Haloperidol, or Risperidone

Abstract: Objective Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses. Method Six-week body-weight data from 2 trials, study 1 comparing olanzapine and haloperidol (N = 1,369) and study 2 olanzapine and risperidone (N = 268), were analyzed. Effects of 8 clinically relevant covariates--therapy, clinical outcome (Brief Psychiatric Rating Scale), baseline body mass index (BBMI), increased appetite, age, gender, race, and dose--on weight were compared. Results In study 1, olanzapine (vs. haloperidol) therapy, better clinical outcome, lower BBMI, and nonwhite race significantly affected weight gain. Effects of increased appetite and male gender on weight gain were significant for olanzapine but not for haloperidol. In study 2, better clinical outcome, lower BBMI, and younger age significantly affected weight gain. Increased appetite was more frequent during olanzapine treatment than during haloperidol, but not significantly different from risperidone. Significant differences in effect on weight change were found between olanzapine and haloperidol but not between olanzapine and risperidone. No evidence was found that lower antipsychotic drug doses were associated with lower weight gain. Conclusion This report identifies predictive factors of acute weight change in patients with schizophrenia. Similar factors across antipsychotic drugs in predicting greater weight gain included better clinical outcome, low BBMI, and nonwhite race. Factors differing between conventional (haloperidol) and atypical (olanzapine) agents included increased appetite and gender. Choice of atypical antipsychotic drug (olanzapine vs. risperidone) was of minor importance with regard to influence on acute weight gain.

Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.

Abstract: Objective This study assesses the efficacy and tolerability of fluoxetine in the acute treatment of child and adolescent obsessive-compulsive disorder (OCD) during a 13-week, double-blind, placebo-controlled study. Method Eligible patients aged 7 to 17 (N = 103) were randomized at a ratio of 2:1 to receive either fluoxetine or placebo. Dosing was initiated at 10 mg daily for 2 weeks, then increased to 20 mg daily. After 4 weeks of treatment, and again after 7 weeks of treatment, nonresponders could have their dosage increased by 20 mg daily, for a maximum possible dosage of 60 mg daily. Primary measure of efficacy was improvement in OCD symptoms as measured by the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS). All analyses were intent-to-treat. Results Fluoxetine was associated with significantly greater improvement in OCD as assessed by the CY-BOCS (p = .026) and other measures than was placebo. Fluoxetine was well tolerated and had a rate of discontinuation for adverse events similar to that of placebo (p = 1.00). Conclusions Fluoxetine 20 to 60 mg daily was effective and well tolerated for treatment of OCD in this pediatric population.

Reduced levels of amyloid β-peptide antibody in Alzheimer disease

Abstract: Objective: To investigate whether it was possible to detect the presence and different levels of naturally occurring anti-β-amyloid (Aβ) antibodies in the CSF of patients with AD and age-matched controls by employing a sensitive ELISA. Background: Immunization with preaggregated amyloid β-peptide (Aβ 1–42 ) and administration of antibodies against Aβ into amyloid precursor protein APP V717F – transgenic mice (an animal model of AD) have recently been reported to dramatically reduce amyloid plaque deposition, neuritic dystrophy, and astrogliosis, most likely by enhancing Aβ clearance from brain. Methods: A sensitive ELISA was performed to detect levels of naturally occurring anti-Aβ antibodies in the CSF of patients with AD and age-matched controls. Additionally, an immunoprecipitation assay was performed to confirm that naturally occurring anti-Aβ antibodies also exist in the human blood. Result: Naturally occurring antibodies directed against Aβ were found in the CSF and plasma of patients with AD and healthy control subjects. Moreover, CSF anti-Aβ antibody titers are significantly lower in patients with AD compared with healthy control subjects. Conclusion: Naturally occurring antibodies directed against Aβ exist in human CSF and plasma. The CSF anti-Aβ antibody titers may be helpful in better understanding the effects of future immunologic therapies for AD.